{"gene":"NOTCH3","run_date":"2026-06-10T05:19:52","timeline":{"discoveries":[{"year":1996,"finding":"Mutations in the NOTCH3 gene were identified as causative for CADASIL; the mutations map to the CADASIL critical region on chromosome 19 and cause serious disruption of the Notch3 receptor, establishing NOTCH3 as the defective gene in CADASIL patients.","method":"Positional cloning, sequence analysis, genetic linkage analysis","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 / Strong — positional cloning with co-segregation analysis, replicated across multiple families, foundational discovery replicated by many subsequent studies","pmids":["8878478"],"is_preprint":false},{"year":1997,"finding":"CADASIL mutations in NOTCH3 are strongly clustered within the EGF-like repeats of the extracellular domain and are stereotyped missense mutations that all cause loss or gain of a cysteine residue, resulting in an unpaired number of cysteine residues within a given EGF domain; this suggests aberrant dimerization of Notch3 via abnormal disulfide bridging.","method":"SSCP, heteroduplex analysis, Sanger sequencing of 50 unrelated CADASIL patients and 100 controls","journal":"Lancet","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct mutational screening with controls, replicated in many subsequent studies across populations","pmids":["9388399"],"is_preprint":false},{"year":2000,"finding":"In normal tissues NOTCH3 expression is restricted to vascular smooth muscle cells; NOTCH3 undergoes proteolytic cleavage producing a 210-kDa extracellular fragment and a 97-kDa intracellular fragment; in CADASIL brains the 210-kDa ectodomain selectively accumulates at the cytoplasmic membrane of vascular smooth muscle cells, while the cytosolic domain does not accumulate, indicating that CADASIL mutations specifically impair clearance of the Notch3 ectodomain from the cell surface.","method":"Immunohistochemistry, Western blot, transfected cell analysis, post-mortem CADASIL brain tissue analysis","journal":"Journal of Clinical Investigation","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (IHC, Western blot, cell transfection), replicated finding across patient samples","pmids":["10712431"],"is_preprint":false},{"year":2005,"finding":"CADASIL mutations in NOTCH3 do not affect the addition of O-fucose to EGF-like repeats but do impair carbohydrate chain elongation by Fringe (O-fucosyltransferase-dependent glycosylation); additionally, CADASIL mutations induce aberrant homodimerization of mutant Notch3 fragments and heterodimerization with Lunatic Fringe, implicating Fringe in CADASIL pathophysiology.","method":"Biochemical glycosylation assays on Notch3 EGF-like repeat fragments, in vitro dimerization assays","journal":"Human Molecular Genetics","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro biochemical assay with mutant constructs, multiple orthogonal readouts in single study","pmids":["15857853"],"is_preprint":false},{"year":2007,"finding":"The archetypal CADASIL mutation R90C in NOTCH3 retains normal canonical Notch signaling activity in brain arteries in vivo (normal RBP-Jk-mediated activity) and does not exhibit dominant-negative activity even when the ectodomain accumulates; this suggests CADASIL pathogenesis involves novel pathogenic roles of mutant NOTCH3 rather than loss of canonical NOTCH3 signaling function.","method":"Genetic rescue experiments in Notch3-/- mice using transgenic expression of wild-type or R90C mutant human NOTCH3 at physiological levels; in vivo NOTCH3/RBP-Jk activity assessment","journal":"Human Molecular Genetics","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — genetic epistasis/rescue in vivo with functional signaling readout, rigorous comparison of WT vs mutant at matched expression levels","pmids":["17331978"],"is_preprint":false},{"year":2009,"finding":"Both wild-type and CADASIL-mutated NOTCH3 ectodomain spontaneously form oligomers and higher-order multimers via disulfide bonds in vitro; CADASIL-associated mutations significantly enhance multimerization compared to wild-type, providing experimental evidence for a neomorphic effect of CADASIL mutations promoting N3ECD self-association and accumulation.","method":"In vitro multimerization assays, single-molecule analysis ('scanning for intensely fluorescent targets'), biochemical characterization","journal":"Human Molecular Genetics","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution with single-molecule analysis, multiple methods in one study","pmids":["19417009"],"is_preprint":false},{"year":2009,"finding":"Thrombospondin-2 (TSP2), but not TSP1, directly binds to NOTCH3 and Jagged1 and augments the interaction between Notch3 and Jagged1, thereby enhancing Notch3 signal transduction potency; loss of TSP2 in knockout mice reduces Notch target gene expression, identifying TSP2 as an extracellular intermediary that facilitates Notch3-Jagged1 receptor-ligand interactions.","method":"Direct binding assays (TSP2 pulldown with Notch3 and Jagged1), TSP2 knockout mouse analysis, Notch target gene expression measurement, cancer cell proliferation assays","journal":"Journal of Biological Chemistry","confidence":"High","confidence_rationale":"Tier 2 / Moderate — direct binding demonstrated, genetic KO validation with functional readout, multiple orthogonal methods","pmids":["19147503"],"is_preprint":false},{"year":2009,"finding":"Degradation of both the intracellular domain (N3-ICD) and the extracellular domain (N3-ECD) of Notch3 is mediated by lysosomes, not by the ubiquitin-proteasome system; lysosome inhibitors (chloroquine, NH4Cl) caused accumulation and delayed degradation of N3-ICD, while proteasome inhibitors (MG132, lactacystin) had no effect, distinguishing Notch3 turnover from Notch1 and Notch4.","method":"Pharmacological inhibitor experiments (lysosome vs. proteasome inhibitors) in transfected 293 cells and endogenous N3-ICD in C2C12, H460, and HeLa cell lines; Western blot","journal":"International Journal of Biochemistry & Cell Biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple cell lines, multiple inhibitors, direct comparison of lysosome vs. proteasome pathways, consistent results","pmids":["19735738"],"is_preprint":false},{"year":2010,"finding":"Notch3 is required in mural cells for retinal vascular development; Notch3-deficient mice exhibit reduced retinal vascularization, diminished sprouting, reduced mural cell investment, and loss of vessel coverage; Notch3 also regulates angiopoietin-2 expression in mural cells (Notch3 is sufficient for angiopoietin-2 induction, enhanced by HIF-1α), and pathological neovascularization in oxygen-induced retinopathy is decreased in Notch3-null mice.","method":"Notch3 knockout mice, oxygen-induced retinopathy model, in vitro Notch3 overexpression assays for angiopoietin-2 induction, immunostaining","journal":"Circulation Research","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO with defined vascular phenotype, in vitro mechanistic validation, multiple readouts","pmids":["20689064"],"is_preprint":false},{"year":2012,"finding":"NOTCH3 forms heterodimers with NOTCH1, NOTCH3, and NOTCH4; CADASIL mutant NOTCH3 (R90C, C49Y) forms complexes more resistant to detergents than wild-type; mutant NOTCH3 shows significantly inhibited clearance; overexpressed wild-type and mutant NOTCH3 protein repress NOTCH-regulated smooth muscle transcripts and impair the activity of smooth muscle promoters, suggesting that NOTCH3 accumulation interferes with canonical Notch function in smooth muscle cells.","method":"Co-immunoprecipitation for heterodimer detection, quantitative NOTCH3-luciferase clearance assays, coculture NOTCH functional assays, smooth muscle promoter reporter assays","journal":"PLoS One","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal co-IP and functional reporter assays, single lab, multiple orthogonal methods","pmids":["23028706"],"is_preprint":false},{"year":2014,"finding":"Ligand-induced proteolytic activation of NOTCH3 (and NOTCH2) requires sequential cleavage by ADAM10 metalloprotease followed by intramembranous cleavage by the presenilin-containing γ-secretase complex; ADAM17/TACE plays no role in ligand-induced NOTCH2 or NOTCH3 signaling, establishing canonical ligand-induced processing of NOTCH3 as strictly ADAM10- and presenilin-dependent.","method":"Cell-based proteolytic activation assays with Delta-Jagged-type ligands, ADAM10 and presenilin knockdown/knockout, signaling readouts","journal":"Molecular and Cellular Biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic knockouts combined with functional signaling readouts, explicit negative result for ADAM17, rigorous mechanistic dissection","pmids":["24842903"],"is_preprint":false},{"year":2014,"finding":"LTBP-1 (latent TGF-β binding protein 1) directly interacts with NOTCH3-ECD and co-aggregates specifically with mutant Notch3-ECD deposits in CADASIL vessel walls; fibronectin and fibrillin-1 are also enriched in CADASIL vessels but do not co-localize with Notch3-ECD deposits; TGF-β prodomain (LAP) levels are increased in CADASIL, indicating dysregulation of TGF-β pathway via sequestration by Notch3-ECD aggregates.","method":"Immunohistochemistry of post-mortem CADASIL brain tissue, in vitro direct interaction assay between LTBP-1 and Notch3-ECD, co-aggregation assays","journal":"Acta Neuropathologica Communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct binding demonstrated in vitro plus IHC in patient tissue, single lab","pmids":["25190493"],"is_preprint":false},{"year":2015,"finding":"Endogenous Notch3 signaling via Jag1 and Jag2 ligands selectively controls the pool of undifferentiated progenitors of upper airways; disruption of Notch3 signaling (genetic and pharmacological) causes aberrant expansion of basal cells and altered pseudostratification; Notch3-dependent parabasal cells subsequently activate Notch1 and Notch2 for secretory-multiciliated cell fate selection.","method":"Genetic knockouts, pharmacological inhibition, airway organotypic culture, human lung tissue analysis","journal":"Development","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic and pharmacological approaches combined, defined cellular phenotype with pathway placement, validated in human tissue","pmids":["25564622"],"is_preprint":false},{"year":2016,"finding":"Notch3 drives cholangiocarcinoma development and progression via a non-canonical pathway independent of RBPJ; Notch3 promotes tumor cell survival via activation of PI3K-Akt; genetic knockout of Notch3 significantly attenuates tumor growth.","method":"Notch3 genetic knockout studies in transgenic mouse model and rat model, PI3K-Akt pathway analysis, human CC characterization","journal":"Proceedings of the National Academy of Sciences","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO with defined tumor growth phenotype, mechanistic pathway identification (PI3K-Akt), validated across species","pmids":["27791012"],"is_preprint":false},{"year":2017,"finding":"Notch3 signaling is both necessary and sufficient to support mural cell coverage in arteries; systemic administration of an agonist Notch3 antibody prevents mural cell loss in CADASIL mice (C455R mutation) and modifies plasma proteins including endostatin/collagen 18α1 and Notch3 ECD; genetic rescue in Notch3 knockout mice demonstrated necessity and sufficiency of Notch3 for mural cell maintenance.","method":"Genetic rescue in Notch3 knockout mice, agonist antibody treatment in CADASIL mouse model, plasma protein analysis","journal":"Journal of Experimental Medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic rescue with KO mice plus pharmacological agonist antibody, multiple readouts including plasma biomarkers","pmids":["28698285"],"is_preprint":false},{"year":2017,"finding":"Notch3 functions as a dependence receptor in endothelial cells, inducing apoptosis in the absence of its ligand Jagged-1; Jagged-1 produced by cancer cells blocks this pro-apoptotic activity; using Notch3 mutant mice, tumor growth and angiogenesis increase when Notch3 is silenced in stroma, and the anti-tumor effect of γ-secretase inhibition is partly dependent on Notch3-triggered apoptosis in endothelial cells.","method":"Notch3 mutant mice, genetic silencing, endothelial cell apoptosis assays, tumor implantation models","journal":"Nature Communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO with tumor growth phenotype, mechanistic apoptosis assays, multiple experimental models","pmids":["28719575"],"is_preprint":false},{"year":2017,"finding":"NOTCH3 is expressed in NG2+PDGFRβ+ perivascular hemangioma stem cells (HemSCs) and is necessary for HemSC-to-mural cell differentiation; NOTCH3 knockdown in HemSCs inhibits mural cell differentiation and perturbs αSMA expression; in a mouse IH model, NOTCH3 knockdown or NOTCH3 Decoy expression decreases IH blood flow, vessel caliber, and αSMA+ perivascular cell coverage.","method":"NOTCH3 knockdown in HemSCs, mouse IH model, NOTCH3 Decoy transgenic expression, flow cytometry, immunostaining","journal":"JCI Insight","confidence":"High","confidence_rationale":"Tier 2 / Strong — loss-of-function with defined cellular phenotype in vitro and in vivo, multiple orthogonal approaches","pmids":["29093274"],"is_preprint":false},{"year":2019,"finding":"CADASIL vasculopathy involves a Notch3-Nox5/ER stress/ROCK signaling mechanism; NOTCH3 mutations in VSMCs induce Nox5 upregulation, leading to increased ER stress response, Rho kinase activity, superoxide production, and cytoskeleton-associated protein phosphorylation; inhibitors of Notch3 (γ-secretase inhibitor), Nox5, ER stress, and ROCK each ameliorate aberrant vascular responses in CADASIL patient arteries and TgNotch3R169C mice.","method":"Peripheral small artery isolation from CADASIL patients and CADASIL mouse model, pharmacological inhibitors, gene expression analysis, functional vascular assays","journal":"JCI Insight","confidence":"High","confidence_rationale":"Tier 2 / Strong — human patient tissue plus mouse model, multiple pharmacological interventions with consistent results, pathway placement established","pmids":["31647781"],"is_preprint":false},{"year":2019,"finding":"MMP14 nuclear translocation following TMZ treatment promotes extracellular release of DLL4, which stimulates cleavage of Notch3 and its nuclear translocation, inducing sphering capacity and stemness in glioblastoma cells.","method":"Subcellular localization studies, Kiloplex ELISA-based array, functional stemness assays in PDX GBM models and established cell lines","journal":"International Journal of Cancer","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — mechanistic pathway placement with functional readouts, single lab, limited mechanistic depth for NOTCH3 specifically","pmids":["31443114"],"is_preprint":false},{"year":2021,"finding":"Pericyte NOTCH3 and endothelial NOTCH1 cooperate for pericyte-induced stabilization of the vasculature; loss of either NOTCH3 or NOTCH1 decreases VE-cadherin accumulation at endothelial adherens junctions and increases junction motility; DLL4 is the key ligand for NOTCH1 activation in endothelial cells, and DLL4 expression in pericytes is dependent on NOTCH3.","method":"In vitro vascular models with pericyte-endothelial coculture, NOTCH3 and NOTCH1 loss-of-function, VE-cadherin imaging, DLL4 expression analysis","journal":"American Journal of Physiology: Cell Physiology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — defined cellular phenotype with loss-of-function, pathway placement via ligand identification, multiple readouts in single study","pmids":["34878922"],"is_preprint":false},{"year":2022,"finding":"In elastin deficiency, reduced elastin induces epigenetic upregulation of the NOTCH pathway in SMCs, specifically activating NOTCH3 intracellular domain via increased γ-secretase; JAGGED1 produced by SMCs (not endothelial cells) is the key ligand driving NOTCH3 activation; Notch3 deletion or γ-secretase inhibition attenuates aortic hypermuscularization and stenosis in Eln-/- mice.","method":"Human aortic vascular cells, Eln-/- mouse models, iPSC-derived SMCs from ELN-deficient patients, Notch3 genetic deletion, Jag1 conditional deletion in SMCs vs ECs, pharmacological γ-secretase inhibition","journal":"Journal of Clinical Investigation","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO with cell-type-specific conditional deletion, human and mouse models, multiple orthogonal methods","pmids":["34990407"],"is_preprint":false},{"year":2024,"finding":"Wild-type Notch3-ECD co-aggregates with mutant Notch3-ECD; elimination of one copy of wild-type Notch3 in TgNotch3R169C mice is sufficient to attenuate Notch3-ECD accumulation and arterial pathology (SMC loss); Notch3-regulated gene expression is essentially unchanged in TgNotch3R169C arteries, indicating that ECD accumulation (not loss of signaling) is the major driver of arterial SMC loss in CADASIL.","method":"Dedicated histopathological and multiscale imaging modalities in transgenic and knockin Notch3 mouse models, quantitative SMC loss measurement, Notch3-regulated gene expression profiling, co-aggregation assays","journal":"Journal of Clinical Investigation","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple mouse genetic models (transgenic vs knockin), quantitative pathology, gene expression profiling, direct co-aggregation evidence","pmids":["38386425"],"is_preprint":false},{"year":2016,"finding":"CHAC1, upregulated by TMZ via the JNK1/c-JUN pathway, binds directly to the Notch3 protein and inhibits Notch3 activation, attenuating Notch3-mediated downstream signaling; TMZ also significantly reduces Notch3 levels in glioma cells.","method":"Transcriptome microarray, CHAC1 overexpression/knockdown, co-immunoprecipitation of CHAC1 with Notch3, signaling pathway analysis in GBM cell lines","journal":"Neuropharmacology","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — co-IP demonstrating CHAC1-Notch3 binding, functional signaling readout, single lab","pmids":["27986595"],"is_preprint":false},{"year":2016,"finding":"N-acetylcysteine (NAC) reduces Notch3 (specifically the cleaved intracellular domain N3ICD) protein levels through lysosome-dependent degradation in a manner independent of γ-secretase or glutathione; NAC does not affect full-length Notch3 precursor or ectopically expressed N3ICD, and does not alter Notch3 mRNA, indicating post-translational regulation at the level of processed N3ICD.","method":"Pharmacological inhibition (lysosome vs. proteasome inhibitors), NAC treatment in HeLa and multiple cancer cell lines, Western blot, mRNA analysis, Notch3 silencing and N3ICD overexpression","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple cell lines, multiple inhibitors, orthogonal genetic and pharmacological approaches, single lab","pmids":["27102435"],"is_preprint":false},{"year":2018,"finding":"Deregulated Notch3 signaling enhances CXCR4 cell-surface expression and migratory ability of CD4+CD8+ thymocytes; Notch3 regulates CXCR4 surface expression through β-arrestin in human leukemia cells; in vivo CXCR4 antagonism prevents bone marrow colonization by CD4+CD8+ cells in young Notch3 transgenic mice.","method":"Notch3 intracellular domain transgenic mice, transplantation assays, CXCR4 surface expression analysis, β-arrestin mechanistic studies in human leukemia cells, in vivo CXCR4 antagonism","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — transgenic mouse model with in vivo pharmacological intervention, mechanistic β-arrestin finding in human cells, single lab","pmids":["30038265"],"is_preprint":false},{"year":2020,"finding":"Naturally occurring NOTCH3 exon 9 skipping in a patient with a Gly498Cys NOTCH3 variant effectively excludes the mutation from the majority of transcripts, resulting in attenuated NOTCH3 protein aggregation (no GOM detected, minimal NOTCH3 staining in skin biopsy) and a milder CADASIL phenotype; therapeutic exon 9 skipping can be achieved in cell models using antisense oligonucleotides and CRISPR/Cas9, providing proof-of-concept that cysteine-corrective exon skipping reduces NOTCH3 aggregation.","method":"RT-PCR and Sanger sequencing of patient fibroblast RNA, skin biopsy electron microscopy and immunohistochemistry, antisense-mediated exon skipping in cell models, CRISPR/Cas9 genome editing","journal":"Human Molecular Genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — natural human experiment plus cell model validation with two orthogonal therapeutic approaches, direct biochemical measurement of aggregation","pmids":["31960911"],"is_preprint":false}],"current_model":"NOTCH3 is a transmembrane receptor expressed predominantly in vascular smooth muscle cells and pericytes that undergoes regulated proteolysis (ADAM10 then γ-secretase/presenilin) to release a 210-kDa ectodomain and a 97-kDa intracellular domain (N3-ICD) whose degradation is lysosome-dependent; the receptor signals canonically via RBP-Jk to control arterial SMC identity and mural cell investment of vessels, acts non-canonically (RBPJ-independent, PI3K-Akt) in some contexts, and functions as a dependence receptor in endothelial cells; CADASIL-causing cysteine mutations in the EGF-like repeats of the ectodomain impair Fringe-mediated glycosylation and dramatically enhance disulfide bond-mediated ectodomain multimerization, causing selective accumulation of the 210-kDa ectodomain (together with wild-type ectodomain) at the SMC surface—this aggregation sequesters extracellular matrix proteins such as LTBP-1, activates ER stress and Rho kinase via Nox5, and drives progressive arterial SMC loss, while canonical Notch3 signaling activity per se is largely preserved."},"narrative":{"mechanistic_narrative":"NOTCH3 is a single-pass transmembrane receptor expressed predominantly in vascular smooth muscle cells and mural/pericyte populations, where it governs mural cell investment and stabilization of the developing and mature vasculature [PMID:10712431, PMID:20689064, PMID:28698285]. Ligand engagement triggers sequential proteolysis—an ADAM10 metalloprotease cut followed by intramembranous cleavage by the presenilin-containing γ-secretase complex—releasing a ~210-kDa ectodomain and a ~97-kDa intracellular domain (N3-ICD), both of which are cleared through lysosome-dependent rather than proteasomal degradation [PMID:10712431, PMID:24842903, PMID:19735738]. Canonically NOTCH3 signals through RBP-Jk to specify smooth muscle/mural cell programs, and this activity drives mural cell coverage of arteries and cooperates with endothelial NOTCH1 to maintain VE-cadherin junctions [PMID:28698285, PMID:34878922]; ligand availability is shaped by extracellular intermediaries including Thrombospondin-2, which bridges NOTCH3 to Jagged1 [PMID:19147503], and by Jagged1 produced within smooth muscle, which drives NOTCH3 activation in elastin deficiency [PMID:34990407]. Beyond this canonical axis, NOTCH3 acts non-canonically through PI3K-Akt to promote tumor cell survival in cholangiocarcinoma [PMID:27791012] and behaves as a dependence receptor in endothelial cells, inducing apoptosis when Jagged-1 is absent [PMID:28719575]. NOTCH3 is the causative gene in CADASIL, where stereotyped cysteine-altering missense mutations in the EGF-like repeats of the ectodomain create unpaired cysteines [PMID:8878478, PMID:9388399]; these mutations impair Fringe-mediated glycosylation and dramatically enhance disulfide-bonded ectodomain multimerization, causing selective surface accumulation of the 210-kDa ectodomain together with co-aggregating wild-type ectodomain [PMID:15857853, PMID:19417009, PMID:38386425]. This aggregation, rather than loss of canonical signaling, drives arterial smooth muscle cell loss—canonical RBP-Jk activity is preserved in mutant receptors—and operates by sequestering matrix proteins such as LTBP-1 and engaging a Nox5/ER stress/Rho-kinase cascade [PMID:17331978, PMID:25190493, PMID:31647781, PMID:38386425].","teleology":[{"year":1997,"claim":"Having established NOTCH3 as the CADASIL gene, the question became what kind of lesion the mutations represent; finding that they are stereotyped cysteine gains/losses clustered in ectodomain EGF repeats defined a mutational signature and predicted abnormal disulfide bridging.","evidence":"Mutational screening of CADASIL patients and controls by SSCP, heteroduplex analysis, and Sanger sequencing, following positional cloning","pmids":["8878478","9388399"],"confidence":"High","gaps":["Did not show how unpaired cysteines lead to protein-level dysfunction","No demonstration of aggregation in tissue at this stage"]},{"year":2000,"claim":"It was unknown which NOTCH3 fragment is affected in disease; demonstrating that the 210-kDa ectodomain selectively accumulates at the VSMC surface in CADASIL brains while the intracellular domain does not established a clearance defect specific to the ectodomain.","evidence":"IHC, Western blot, and transfected cell analysis of post-mortem CADASIL brain tissue","pmids":["10712431"],"confidence":"High","gaps":["Did not establish whether accumulation is cause or consequence of disease","Mechanism of impaired ectodomain clearance not defined"]},{"year":2005,"claim":"To explain how cysteine mutations cause accumulation, glycosylation and dimerization were tested; mutations were shown to spare O-fucose addition but impair Fringe-mediated chain elongation and to drive aberrant homo/heterodimerization, implicating glycosylation and abnormal self-association in pathology.","evidence":"In vitro biochemical glycosylation and dimerization assays on Notch3 EGF-like repeat fragments","pmids":["15857853"],"confidence":"High","gaps":["Used isolated fragments rather than full-length receptor","Did not quantify multimerization or link to tissue accumulation"]},{"year":2007,"claim":"A central question was whether CADASIL is loss- or gain-of-function; in vivo rescue showing R90C retains normal RBP-Jk activity and lacks dominant-negative effect established that pathogenesis involves a novel toxic role rather than canonical signaling loss.","evidence":"Genetic rescue in Notch3-/- mice with WT or R90C human NOTCH3 at physiological levels, with in vivo signaling readout","pmids":["17331978"],"confidence":"High","gaps":["Did not identify the toxic mechanism downstream of ectodomain accumulation","Single mutation tested"]},{"year":2009,"claim":"The biophysical basis of accumulation was unresolved; single-molecule and biochemical assays showed both WT and mutant ectodomains form disulfide-linked multimers with mutations markedly enhancing multimerization, providing direct evidence for a neomorphic self-association defect, while parallel work assigned NOTCH3 turnover to the lysosome.","evidence":"In vitro multimerization and single-molecule fluorescence assays; pharmacological lysosome vs proteasome inhibitor experiments across multiple cell lines","pmids":["19417009","19735738"],"confidence":"High","gaps":["Did not reconstitute multimerization in vivo at this stage","Lysosomal targeting signal/machinery not identified"]},{"year":2009,"claim":"How NOTCH3-ligand engagement is modulated extracellularly was unclear; identifying Thrombospondin-2 as a direct binder of NOTCH3 and Jagged1 that augments their interaction defined an extracellular amplifier of NOTCH3 signaling.","evidence":"Direct binding/pulldown assays, TSP2 knockout mouse analysis, and Notch target gene expression","pmids":["19147503"],"confidence":"High","gaps":["TSP2 role in CADASIL or vascular maintenance not tested","Structural basis of the ternary interaction unknown"]},{"year":2010,"claim":"The physiological vascular role of NOTCH3 was incompletely defined; knockout mice revealed it is required in mural cells for retinal vascularization, sprouting, and vessel coverage, and regulates angiopoietin-2, placing NOTCH3 in mural cell investment of vessels.","evidence":"Notch3 knockout mice, oxygen-induced retinopathy model, in vitro angiopoietin-2 induction assays, immunostaining","pmids":["20689064"],"confidence":"High","gaps":["Did not resolve which ligands drive this in vivo","Connection to CADASIL SMC loss not established"]},{"year":2012,"claim":"Whether mutant NOTCH3 might also impair canonical function was revisited; co-IP and reporter assays showed mutant heterodimers are detergent-resistant and poorly cleared and that NOTCH3 overexpression represses smooth muscle transcripts, raising a possible interference with canonical function in SMCs.","evidence":"Reciprocal co-IP for heterodimer detection, NOTCH3-luciferase clearance assays, and smooth muscle promoter reporter assays","pmids":["23028706"],"confidence":"Medium","gaps":["Relied on overexpression, which may not reflect physiological signaling","Apparent tension with in vivo rescue showing preserved signaling not resolved"]},{"year":2014,"claim":"The proteases required for NOTCH3 activation were undefined; functional assays established ligand-induced activation requires ADAM10 then presenilin/γ-secretase, with ADAM17/TACE playing no role, defining the canonical processing pathway.","evidence":"Cell-based proteolytic activation assays with ADAM10/presenilin knockdown-knockout and signaling readouts","pmids":["24842903"],"confidence":"High","gaps":["Did not address ligand-independent or aberrant processing in disease","Regulation of protease access not studied"]},{"year":2014,"claim":"The matrix consequences of ectodomain aggregation were unknown; identifying LTBP-1 as a direct binder that co-aggregates specifically with mutant Notch3-ECD deposits, with increased TGF-β prodomain levels, established sequestration of matrix/TGF-β components as a pathogenic mechanism.","evidence":"IHC of post-mortem CADASIL tissue plus in vitro direct interaction and co-aggregation assays","pmids":["25190493"],"confidence":"Medium","gaps":["Functional consequence of TGF-β dysregulation for SMC loss not demonstrated","Single-lab IHC correlation"]},{"year":2015,"claim":"NOTCH3's role in non-vascular tissue was unclear; airway studies showed endogenous NOTCH3 signaling via Jag1/Jag2 controls undifferentiated progenitor pools and precedes NOTCH1/NOTCH2-driven fate selection, extending NOTCH3 function to epithelial progenitor regulation.","evidence":"Genetic knockouts, pharmacological inhibition, airway organotypic culture, and human lung tissue analysis","pmids":["25564622"],"confidence":"High","gaps":["Downstream transcriptional targets in airway not detailed","Relevance to vascular NOTCH3 biology not connected"]},{"year":2016,"claim":"Whether NOTCH3 signals only canonically was tested in cancer; cholangiocarcinoma studies showed NOTCH3 drives tumor survival and growth via an RBPJ-independent PI3K-Akt pathway, establishing a non-canonical NOTCH3 mode.","evidence":"Notch3 genetic knockout in mouse and rat models, PI3K-Akt pathway analysis, human tumor characterization","pmids":["27791012"],"confidence":"High","gaps":["Molecular link between NOTCH3 and PI3K-Akt not defined","Generality across tumor types untested here"]},{"year":2016,"claim":"Post-translational control of N3-ICD was probed pharmacologically; CHAC1 was shown to bind NOTCH3 and inhibit its activation, and N-acetylcysteine was shown to lower cleaved N3-ICD via lysosomal degradation, identifying modulators of NOTCH3 protein levels and signaling.","evidence":"Co-IP of CHAC1 with NOTCH3 and signaling assays; NAC treatment with lysosome/proteasome inhibitors, silencing, and N3ICD overexpression across cancer cell lines","pmids":["27986595","27102435"],"confidence":"Medium","gaps":["CHAC1-NOTCH3 interaction is single-lab co-IP without structural detail","NAC mechanism on endogenous N3ICD versus ectopic differs and is unexplained"]},{"year":2017,"claim":"The vascular dependence of NOTCH3 and its therapeutic accessibility were addressed together; genetic rescue and agonist antibody studies showed NOTCH3 is necessary and sufficient for arterial mural cell coverage and that agonism prevents mural cell loss in CADASIL mice, while separate work defined NOTCH3 as an endothelial dependence receptor inducing ligand-free apoptosis, and as essential for hemangioma stem cell-to-mural differentiation.","evidence":"Genetic rescue in Notch3 KO mice and agonist antibody treatment in CADASIL mice; dependence-receptor apoptosis assays in tumor models; NOTCH3 knockdown/Decoy in HemSCs and IH mouse model","pmids":["28698285","28719575","29093274"],"confidence":"High","gaps":["How the same receptor balances survival/mural-supportive and pro-apoptotic outputs not mechanistically unified","Agonist antibody durability and specificity not fully characterized"]},{"year":2019,"claim":"A downstream effector cascade for CADASIL vasculopathy was missing; mutant NOTCH3 was shown to upregulate Nox5, raising ER stress, ROCK activity, and superoxide, with inhibitors of each step ameliorating aberrant vascular responses in patient arteries and mutant mice, defining a Nox5/ER stress/ROCK axis. In parallel, ligand-induced NOTCH3 cleavage and nuclear translocation were linked to glioblastoma stemness via MMP14/DLL4.","evidence":"CADASIL patient and mouse small-artery isolation with pharmacological inhibitors and functional vascular assays; subcellular localization and stemness assays in GBM models","pmids":["31647781","31443114"],"confidence":"High","gaps":["Connection between ectodomain aggregation and intracellular Nox5 induction not fully resolved","GBM MMP14/DLL4/NOTCH3 axis is single-lab and Medium confidence"]},{"year":2020,"claim":"A causal test of aggregation as the disease driver and a therapeutic strategy emerged together; natural exon 9 skipping in a Gly498Cys patient excluded the mutant cysteine and yielded attenuated aggregation and milder disease, with antisense and CRISPR approaches reproducing cysteine-corrective skipping, providing proof-of-concept that reducing aggregation is beneficial.","evidence":"Patient fibroblast RT-PCR/sequencing, skin biopsy EM/IHC, and antisense and CRISPR/Cas9 exon-skipping in cell models","pmids":["31960911"],"confidence":"High","gaps":["In vivo efficacy of therapeutic exon skipping not demonstrated","Applicability beyond skippable exons unclear"]},{"year":2021,"claim":"How NOTCH3 cooperates across the vessel wall was unresolved; pericyte-endothelial coculture showed pericyte NOTCH3 and endothelial NOTCH1 cooperate to stabilize VE-cadherin junctions, with DLL4 (NOTCH1 ligand) expression in pericytes dependent on NOTCH3, defining a cross-talk circuit for vascular stabilization.","evidence":"In vitro pericyte-endothelial coculture with NOTCH3/NOTCH1 loss-of-function, VE-cadherin imaging, and DLL4 expression analysis","pmids":["34878922"],"confidence":"High","gaps":["In vivo validation of the NOTCH3→DLL4→NOTCH1 circuit not shown","Relevance to CADASIL pathology not established"]},{"year":2022,"claim":"Context-specific drivers of NOTCH3 activation in disease were defined; in elastin deficiency, reduced elastin epigenetically upregulates NOTCH3 with SMC-derived (not endothelial) JAGGED1 driving N3-ICD generation via increased γ-secretase, and Notch3 deletion or γ-secretase inhibition rescued aortic hypermuscularization and stenosis.","evidence":"Human aortic cells, Eln-/- mice, iPSC-derived patient SMCs, Notch3 deletion, cell-type-specific Jag1 deletion, and γ-secretase inhibition","pmids":["34990407"],"confidence":"High","gaps":["Epigenetic mechanism linking elastin loss to NOTCH3 not fully detailed","Whether this axis operates in CADASIL untested"]},{"year":2024,"claim":"The definitive test of whether accumulation versus signaling loss drives CADASIL was performed; showing wild-type ectodomain co-aggregates with mutant and that removing one wild-type Notch3 copy attenuates ECD accumulation and arterial SMC loss while gene expression is unchanged established ectodomain accumulation as the major pathogenic driver.","evidence":"Transgenic and knockin Notch3 mouse models with multiscale imaging, quantitative SMC-loss measurement, gene expression profiling, and co-aggregation assays","pmids":["38386425"],"confidence":"High","gaps":["Molecular trigger converting surface aggregates to SMC death not fully defined","Translatability of wild-type-allele reduction to patients unestablished"]},{"year":null,"claim":"It remains unresolved how the same NOTCH3 receptor reconciles its canonical RBP-Jk mural-cell program, non-canonical PI3K-Akt survival signaling, and dependence-receptor pro-apoptotic activity, and what molecular event converts surface ectodomain aggregates into the downstream Nox5/ER-stress/ROCK cascade that kills smooth muscle cells.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unifying model linking the three signaling modes","Mechanistic bridge from extracellular aggregation to intracellular stress cascade undefined","Structural basis of mutant ectodomain self-association not solved"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[10,14,19]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[4,21]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[6]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[2,9]},{"term_id":"GO:0005764","term_label":"lysosome","supporting_discovery_ids":[7,23]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[18]},{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[2,11]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[10,13,19]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[8,12,20]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[0,17,21]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[15]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[7,10]}],"complexes":[],"partners":["JAG1","JAG2","DLL4","THBS2","LTBP1","NOTCH1","CHAC1","ADAM10"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q9UM47","full_name":"Neurogenic locus notch homolog protein 3","aliases":[],"length_aa":2321,"mass_kda":243.6,"function":"Functions as a receptor for membrane-bound ligands Jagged1, Jagged2 and Delta1 to regulate cell-fate determination (PubMed:15350543, PubMed:14714274). Upon ligand activation through the released notch intracellular domain (NICD), it forms a transcriptional activator complex with RBPJ/RBPSUH and activates genes of the enhancer of split locus. Affects the implementation of differentiation, proliferation and apoptotic programs (By similarity)","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/Q9UM47/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/NOTCH3","classification":"Not Classified","n_dependent_lines":5,"n_total_lines":1208,"dependency_fraction":0.0041390728476821195},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/NOTCH3","total_profiled":1310},"omim":[{"mim_id":"621313","title":"BRAIN SMALL VESSEL DISEASE 4; BSVD4","url":"https://www.omim.org/entry/621313"},{"mim_id":"621295","title":"CEREBRAL ARTERIOPATHY, AUTOSOMAL RECESSIVE, WITH SUBCORTICAL INFARCTS AND LEUKOENCEPHALOPATHY 1; CARASIL1","url":"https://www.omim.org/entry/621295"},{"mim_id":"621120","title":"DELTA-LIKE NONCANONICAL NOTCH LIGAND 2; DLK2","url":"https://www.omim.org/entry/621120"},{"mim_id":"618564","title":"MICROANGIOPATHY AND LEUKOENCEPHALOPATHY, PONTINE, AUTOSOMAL DOMINANT; PADMAL","url":"https://www.omim.org/entry/618564"},{"mim_id":"615425","title":"EPIDERMOLYSIS BULLOSA SIMPLEX 3, LOCALIZED OR GENERALIZED INTERMEDIATE, WITH BP230 DEFICIENCY; EBS3","url":"https://www.omim.org/entry/615425"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"},{"location":"Plasma membrane","reliability":"Supported"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"blood vessel","ntpm":200.8}],"url":"https://www.proteinatlas.org/search/NOTCH3"},"hgnc":{"alias_symbol":["CASIL"],"prev_symbol":["CADASIL"]},"alphafold":{"accession":"Q9UM47","domains":[{"cath_id":"2.10.25.10","chopping":"343-393","consensus_level":"high","plddt":64.1265,"start":343,"end":393},{"cath_id":"2.10.25.10","chopping":"472-509","consensus_level":"medium","plddt":71.7684,"start":472,"end":509},{"cath_id":"2.10.25.10","chopping":"512-546","consensus_level":"high","plddt":69.9937,"start":512,"end":546},{"cath_id":"-","chopping":"1027-1081","consensus_level":"medium","plddt":70.0007,"start":1027,"end":1081},{"cath_id":"3.30.70.3310","chopping":"1409-1561_1577-1635","consensus_level":"medium","plddt":80.5939,"start":1409,"end":1635}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9UM47","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9UM47-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9UM47-F1-predicted_aligned_error_v6.png","plddt_mean":61.44},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=NOTCH3","jax_strain_url":"https://www.jax.org/strain/search?query=NOTCH3"},"sequence":{"accession":"Q9UM47","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9UM47.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9UM47/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9UM47"}},"corpus_meta":[{"pmid":"8878478","id":"PMC_8878478","title":"Notch3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia.","date":"1996","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/8878478","citation_count":1650,"is_preprint":false},{"pmid":"19539236","id":"PMC_19539236","title":"Cadasil.","date":"2009","source":"The Lancet. Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/19539236","citation_count":857,"is_preprint":false},{"pmid":"9388399","id":"PMC_9388399","title":"Strong clustering and stereotyped nature of Notch3 mutations in CADASIL patients.","date":"1997","source":"Lancet (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/9388399","citation_count":548,"is_preprint":false},{"pmid":"10712431","id":"PMC_10712431","title":"The ectodomain of the Notch3 receptor accumulates within the cerebrovasculature of CADASIL patients.","date":"2000","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/10712431","citation_count":479,"is_preprint":false},{"pmid":"16778208","id":"PMC_16778208","title":"Notch3 gene amplification in ovarian cancer.","date":"2006","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/16778208","citation_count":231,"is_preprint":false},{"pmid":"20689064","id":"PMC_20689064","title":"Notch3 is critical for proper angiogenesis and mural cell investment.","date":"2010","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/20689064","citation_count":156,"is_preprint":false},{"pmid":"27844030","id":"PMC_27844030","title":"Archetypal NOTCH3 mutations frequent in public exome: implications for CADASIL.","date":"2016","source":"Annals of clinical and translational neurology","url":"https://pubmed.ncbi.nlm.nih.gov/27844030","citation_count":155,"is_preprint":false},{"pmid":"19174371","id":"PMC_19174371","title":"Congruence between NOTCH3 mutations and GOM in 131 CADASIL patients.","date":"2009","source":"Brain : a journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/19174371","citation_count":153,"is_preprint":false},{"pmid":"25323668","id":"PMC_25323668","title":"CADASIL and CARASIL.","date":"2014","source":"Brain pathology (Zurich, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/25323668","citation_count":151,"is_preprint":false},{"pmid":"25564622","id":"PMC_25564622","title":"Notch3-Jagged signaling controls the pool of undifferentiated airway progenitors.","date":"2015","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/25564622","citation_count":130,"is_preprint":false},{"pmid":"17854869","id":"PMC_17854869","title":"An overview of Notch3 function in vascular smooth muscle cells.","date":"2007","source":"Progress in biophysics and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/17854869","citation_count":113,"is_preprint":false},{"pmid":"20967782","id":"PMC_20967782","title":"Pathogenesis of CADASIL: transgenic and knock-out mice to probe function and dysfunction of the mutated gene, Notch3, in the cerebrovasculature.","date":"2010","source":"BioEssays : news and reviews in molecular, cellular and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/20967782","citation_count":106,"is_preprint":false},{"pmid":"24844136","id":"PMC_24844136","title":"Interpretation of NOTCH3 mutations in the diagnosis of CADASIL.","date":"2014","source":"Expert review of molecular diagnostics","url":"https://pubmed.ncbi.nlm.nih.gov/24844136","citation_count":99,"is_preprint":false},{"pmid":"17696940","id":"PMC_17696940","title":"Aberrant Notch3 and Notch4 expression in human hepatocellular carcinoma.","date":"2007","source":"Liver international : official journal of the International Association for the Study of the Liver","url":"https://pubmed.ncbi.nlm.nih.gov/17696940","citation_count":95,"is_preprint":false},{"pmid":"9329692","id":"PMC_9329692","title":"Notch3 mutations in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), a mendelian condition causing stroke and vascular dementia.","date":"1997","source":"Annals of the New York Academy of Sciences","url":"https://pubmed.ncbi.nlm.nih.gov/9329692","citation_count":94,"is_preprint":false},{"pmid":"17008611","id":"PMC_17008611","title":"Cortical neuronal apoptosis in CADASIL.","date":"2006","source":"Stroke","url":"https://pubmed.ncbi.nlm.nih.gov/17008611","citation_count":90,"is_preprint":false},{"pmid":"16717210","id":"PMC_16717210","title":"Characteristics of CADASIL in Korea: a novel cysteine-sparing Notch3 mutation.","date":"2006","source":"Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/16717210","citation_count":84,"is_preprint":false},{"pmid":"17331978","id":"PMC_17331978","title":"The archetypal R90C CADASIL-NOTCH3 mutation retains NOTCH3 function in vivo.","date":"2007","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/17331978","citation_count":78,"is_preprint":false},{"pmid":"27791012","id":"PMC_27791012","title":"Notch3 drives development and progression of cholangiocarcinoma.","date":"2016","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/27791012","citation_count":75,"is_preprint":false},{"pmid":"27378579","id":"PMC_27378579","title":"Notch signaling in lung diseases: focus on Notch1 and Notch3.","date":"2016","source":"Therapeutic advances in respiratory disease","url":"https://pubmed.ncbi.nlm.nih.gov/27378579","citation_count":74,"is_preprint":false},{"pmid":"15995828","id":"PMC_15995828","title":"The spectrum of mutations for CADASIL diagnosis.","date":"2005","source":"Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology","url":"https://pubmed.ncbi.nlm.nih.gov/15995828","citation_count":72,"is_preprint":false},{"pmid":"32210034","id":"PMC_32210034","title":"Notch3 in Development, Health and Disease.","date":"2020","source":"Biomolecules","url":"https://pubmed.ncbi.nlm.nih.gov/32210034","citation_count":70,"is_preprint":false},{"pmid":"29622701","id":"PMC_29622701","title":"The Role of Notch3 in Cancer.","date":"2018","source":"The oncologist","url":"https://pubmed.ncbi.nlm.nih.gov/29622701","citation_count":69,"is_preprint":false},{"pmid":"24842903","id":"PMC_24842903","title":"Regulated proteolysis of NOTCH2 and NOTCH3 receptors by ADAM10 and presenilins.","date":"2014","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/24842903","citation_count":69,"is_preprint":false},{"pmid":"18758477","id":"PMC_18758477","title":"Notch3: from subtle structural differences to functional diversity.","date":"2008","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/18758477","citation_count":68,"is_preprint":false},{"pmid":"20935329","id":"PMC_20935329","title":"NOTCH3 mutations and clinical features in 33 mainland Chinese families with CADASIL.","date":"2010","source":"Journal of neurology, neurosurgery, and psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/20935329","citation_count":68,"is_preprint":false},{"pmid":"28902129","id":"PMC_28902129","title":"Systematic Review of Cysteine-Sparing NOTCH3 Missense Mutations in Patients with Clinical Suspicion of CADASIL.","date":"2017","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/28902129","citation_count":68,"is_preprint":false},{"pmid":"19417009","id":"PMC_19417009","title":"CADASIL mutations enhance spontaneous multimerization of NOTCH3.","date":"2009","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19417009","citation_count":66,"is_preprint":false},{"pmid":"20038773","id":"PMC_20038773","title":"Comparison of clinical, familial, and MRI features of CADASIL and NOTCH3-negative patients.","date":"2010","source":"Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/20038773","citation_count":66,"is_preprint":false},{"pmid":"10476042","id":"PMC_10476042","title":"CADASIL: hereditary disease of arteries causing brain infarcts and dementia.","date":"1999","source":"Neuropathology and applied neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/10476042","citation_count":63,"is_preprint":false},{"pmid":"24743243","id":"PMC_24743243","title":"Notch3 pathway alterations in ovarian cancer.","date":"2014","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/24743243","citation_count":62,"is_preprint":false},{"pmid":"16508299","id":"PMC_16508299","title":"CADASIL: a critical look at a Notch disease.","date":"2006","source":"Developmental neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/16508299","citation_count":60,"is_preprint":false},{"pmid":"32732295","id":"PMC_32732295","title":"Broad phenotype of cysteine-altering NOTCH3 variants in UK Biobank: CADASIL to nonpenetrance.","date":"2020","source":"Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/32732295","citation_count":60,"is_preprint":false},{"pmid":"32457593","id":"PMC_32457593","title":"Clinical and Genetic Aspects of CADASIL.","date":"2020","source":"Frontiers in aging neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/32457593","citation_count":58,"is_preprint":false},{"pmid":"19147503","id":"PMC_19147503","title":"Thrombospondin 2 potentiates notch3/jagged1 signaling.","date":"2009","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19147503","citation_count":57,"is_preprint":false},{"pmid":"28698285","id":"PMC_28698285","title":"Therapeutic antibody targeting of Notch3 signaling prevents mural cell loss in CADASIL.","date":"2017","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/28698285","citation_count":57,"is_preprint":false},{"pmid":"20876488","id":"PMC_20876488","title":"CADASIL: experimental insights from animal models.","date":"2010","source":"Stroke","url":"https://pubmed.ncbi.nlm.nih.gov/20876488","citation_count":56,"is_preprint":false},{"pmid":"21045164","id":"PMC_21045164","title":"CADASIL.","date":"2010","source":"Journal of geriatric psychiatry and neurology","url":"https://pubmed.ncbi.nlm.nih.gov/21045164","citation_count":55,"is_preprint":false},{"pmid":"15537516","id":"PMC_15537516","title":"The pathogenesis of CADASIL: an update.","date":"2004","source":"Journal of the neurological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/15537516","citation_count":55,"is_preprint":false},{"pmid":"25190493","id":"PMC_25190493","title":"Sequestration of latent TGF-β binding protein 1 into CADASIL-related Notch3-ECD deposits.","date":"2014","source":"Acta neuropathologica communications","url":"https://pubmed.ncbi.nlm.nih.gov/25190493","citation_count":53,"is_preprint":false},{"pmid":"15857853","id":"PMC_15857853","title":"CADASIL mutations impair Notch3 glycosylation by Fringe.","date":"2005","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/15857853","citation_count":48,"is_preprint":false},{"pmid":"29478611","id":"PMC_29478611","title":"CADASIL.","date":"2018","source":"Handbook of clinical neurology","url":"https://pubmed.ncbi.nlm.nih.gov/29478611","citation_count":47,"is_preprint":false},{"pmid":"21038489","id":"PMC_21038489","title":"CADASIL and migraine: A narrative review.","date":"2010","source":"Cephalalgia : an international journal of headache","url":"https://pubmed.ncbi.nlm.nih.gov/21038489","citation_count":47,"is_preprint":false},{"pmid":"17122431","id":"PMC_17122431","title":"Cholinergic neuronal deficits in CADASIL.","date":"2006","source":"Stroke","url":"https://pubmed.ncbi.nlm.nih.gov/17122431","citation_count":47,"is_preprint":false},{"pmid":"29757481","id":"PMC_29757481","title":"Severe white matter astrocytopathy in CADASIL.","date":"2018","source":"Brain pathology (Zurich, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/29757481","citation_count":46,"is_preprint":false},{"pmid":"27986595","id":"PMC_27986595","title":"The CHAC1-inhibited Notch3 pathway is involved in temozolomide-induced glioma cytotoxicity.","date":"2016","source":"Neuropharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/27986595","citation_count":45,"is_preprint":false},{"pmid":"32348626","id":"PMC_32348626","title":"CADASIL: yesterday, today, tomorrow.","date":"2020","source":"European journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/32348626","citation_count":42,"is_preprint":false},{"pmid":"23028706","id":"PMC_23028706","title":"Biochemical characterization and cellular effects of CADASIL mutants of NOTCH3.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23028706","citation_count":40,"is_preprint":false},{"pmid":"38176524","id":"PMC_38176524","title":"CADASIL: A NOTCH3-associated cerebral small vessel disease.","date":"2024","source":"Journal of advanced research","url":"https://pubmed.ncbi.nlm.nih.gov/38176524","citation_count":39,"is_preprint":false},{"pmid":"30855338","id":"PMC_30855338","title":"CADASIL: new advances in basic science and clinical perspectives.","date":"2019","source":"Current opinion in hematology","url":"https://pubmed.ncbi.nlm.nih.gov/30855338","citation_count":39,"is_preprint":false},{"pmid":"28719575","id":"PMC_28719575","title":"Non-canonical NOTCH3 signalling limits tumour angiogenesis.","date":"2017","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/28719575","citation_count":39,"is_preprint":false},{"pmid":"31647781","id":"PMC_31647781","title":"ER stress and Rho kinase activation underlie the vasculopathy of CADASIL.","date":"2019","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/31647781","citation_count":38,"is_preprint":false},{"pmid":"30014602","id":"PMC_30014602","title":"Notch3ECD immunotherapy improves cerebrovascular responses in CADASIL mice.","date":"2018","source":"Annals of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/30014602","citation_count":38,"is_preprint":false},{"pmid":"35641310","id":"PMC_35641310","title":"Association of NOTCH3 Variant Position With Stroke Onset and Other Clinical Features Among Patients With CADASIL.","date":"2022","source":"Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/35641310","citation_count":38,"is_preprint":false},{"pmid":"34297860","id":"PMC_34297860","title":"NOTCH3 variant position is associated with NOTCH3 aggregation load in CADASIL vasculature.","date":"2021","source":"Neuropathology and applied neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/34297860","citation_count":37,"is_preprint":false},{"pmid":"34878922","id":"PMC_34878922","title":"Notch1 and Notch3 coordinate for pericyte-induced stabilization of vasculature.","date":"2021","source":"American journal of physiology. Cell physiology","url":"https://pubmed.ncbi.nlm.nih.gov/34878922","citation_count":36,"is_preprint":false},{"pmid":"35862191","id":"PMC_35862191","title":"Effect of NOTCH3 EGFr Group, Sex, and Cardiovascular Risk Factors on CADASIL Clinical and Neuroimaging Outcomes.","date":"2022","source":"Stroke","url":"https://pubmed.ncbi.nlm.nih.gov/35862191","citation_count":34,"is_preprint":false},{"pmid":"12681947","id":"PMC_12681947","title":"Notch3, another Notch in T cell development.","date":"2003","source":"Seminars in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/12681947","citation_count":33,"is_preprint":false},{"pmid":"16827154","id":"PMC_16827154","title":"Notch3 intracellular domain accumulates in HepG2 cell line.","date":"2006","source":"Anticancer research","url":"https://pubmed.ncbi.nlm.nih.gov/16827154","citation_count":33,"is_preprint":false},{"pmid":"30038265","id":"PMC_30038265","title":"Intrathymic Notch3 and CXCR4 combinatorial interplay facilitates T-cell leukemia propagation.","date":"2018","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/30038265","citation_count":32,"is_preprint":false},{"pmid":"25060200","id":"PMC_25060200","title":"NOTCH1, NOTCH3, NOTCH4, and JAG2 protein levels in human endometrial cancer.","date":"2014","source":"Medicina (Kaunas, Lithuania)","url":"https://pubmed.ncbi.nlm.nih.gov/25060200","citation_count":31,"is_preprint":false},{"pmid":"36254369","id":"PMC_36254369","title":"Phenotypic variability in 446 CADASIL patients: Impact of NOTCH3 gene mutation location in addition to the effects of age, sex and vascular risk factors.","date":"2022","source":"Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/36254369","citation_count":31,"is_preprint":false},{"pmid":"12756134","id":"PMC_12756134","title":"Incipient CADASIL.","date":"2003","source":"Archives of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/12756134","citation_count":30,"is_preprint":false},{"pmid":"34990407","id":"PMC_34990407","title":"JAGGED1/NOTCH3 activation promotes aortic hypermuscularization and stenosis in elastin deficiency.","date":"2022","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/34990407","citation_count":30,"is_preprint":false},{"pmid":"28416766","id":"PMC_28416766","title":"Notch3 overexpression enhances progression and chemoresistance of urothelial carcinoma.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/28416766","citation_count":30,"is_preprint":false},{"pmid":"35822697","id":"PMC_35822697","title":"Genetic spectrum of NOTCH3 and clinical phenotype of CADASIL patients in different populations.","date":"2022","source":"CNS neuroscience & therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/35822697","citation_count":29,"is_preprint":false},{"pmid":"25692567","id":"PMC_25692567","title":"Clinical significance of cerebral microbleeds locations in CADASIL with R544C NOTCH3 mutation.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25692567","citation_count":29,"is_preprint":false},{"pmid":"27591799","id":"PMC_27591799","title":"CADASIL: Imaging Characteristics and Clinical Correlation.","date":"2016","source":"Current pain and headache reports","url":"https://pubmed.ncbi.nlm.nih.gov/27591799","citation_count":28,"is_preprint":false},{"pmid":"19735738","id":"PMC_19735738","title":"Lysosome-dependent degradation of Notch3.","date":"2009","source":"The international journal of biochemistry & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/19735738","citation_count":28,"is_preprint":false},{"pmid":"28741120","id":"PMC_28741120","title":"CADASIL: Treatment and Management Options.","date":"2017","source":"Current treatment options in neurology","url":"https://pubmed.ncbi.nlm.nih.gov/28741120","citation_count":27,"is_preprint":false},{"pmid":"38386425","id":"PMC_38386425","title":"Protein aggregates containing wild-type and mutant NOTCH3 are major drivers of arterial pathology in CADASIL.","date":"2024","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/38386425","citation_count":26,"is_preprint":false},{"pmid":"33895122","id":"PMC_33895122","title":"Notch3 Signaling and Aggregation as Targets for the Treatment of CADASIL and Other NOTCH3-Associated Small-Vessel Diseases.","date":"2021","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/33895122","citation_count":26,"is_preprint":false},{"pmid":"29093274","id":"PMC_29093274","title":"NOTCH3 regulates stem-to-mural cell differentiation in infantile hemangioma.","date":"2017","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/29093274","citation_count":26,"is_preprint":false},{"pmid":"29158806","id":"PMC_29158806","title":"Correlation of ALDH1 and Notch3 Expression: Clinical implication in Ovarian Carcinomas.","date":"2017","source":"Journal of Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/29158806","citation_count":26,"is_preprint":false},{"pmid":"19006080","id":"PMC_19006080","title":"CADASIL: extended polymorphisms and mutational analysis of the NOTCH3 gene.","date":"2009","source":"Journal of neuroscience research","url":"https://pubmed.ncbi.nlm.nih.gov/19006080","citation_count":25,"is_preprint":false},{"pmid":"17726918","id":"PMC_17726918","title":"Neuropsychiatric manifestations in CADASIL.","date":"2007","source":"Dialogues in clinical neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/17726918","citation_count":25,"is_preprint":false},{"pmid":"38966425","id":"PMC_38966425","title":"Most common NOTCH3 mutations causing CADASIL or CADASIL-like cerebral small vessel disease: A systematic review.","date":"2024","source":"Cerebral circulation - cognition and behavior","url":"https://pubmed.ncbi.nlm.nih.gov/38966425","citation_count":24,"is_preprint":false},{"pmid":"34950895","id":"PMC_34950895","title":"The pericyte: A critical cell in the pathogenesis of CADASIL.","date":"2021","source":"Cerebral circulation - cognition and behavior","url":"https://pubmed.ncbi.nlm.nih.gov/34950895","citation_count":24,"is_preprint":false},{"pmid":"36524456","id":"PMC_36524456","title":"Active immunotherapy reduces NOTCH3 deposition in brain capillaries in a CADASIL mouse model.","date":"2022","source":"EMBO molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/36524456","citation_count":24,"is_preprint":false},{"pmid":"36324403","id":"PMC_36324403","title":"Cognition, mood and behavior in CADASIL.","date":"2022","source":"Cerebral circulation - cognition and behavior","url":"https://pubmed.ncbi.nlm.nih.gov/36324403","citation_count":23,"is_preprint":false},{"pmid":"34335700","id":"PMC_34335700","title":"NOTCH3 Variants and Genotype-Phenotype Features in Chinese CADASIL Patients.","date":"2021","source":"Frontiers in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/34335700","citation_count":23,"is_preprint":false},{"pmid":"31218211","id":"PMC_31218211","title":"NOTCH3 and CADASIL syndrome: a genetic and structural overview.","date":"2019","source":"EMBnet.journal","url":"https://pubmed.ncbi.nlm.nih.gov/31218211","citation_count":23,"is_preprint":false},{"pmid":"25260852","id":"PMC_25260852","title":"Hypomorphic NOTCH3 mutation in an Italian family with CADASIL features.","date":"2014","source":"Neurobiology of aging","url":"https://pubmed.ncbi.nlm.nih.gov/25260852","citation_count":23,"is_preprint":false},{"pmid":"10818516","id":"PMC_10818516","title":"CADASIL: hereditary arteriopathy leading to multiple brain infarcts and dementia.","date":"2000","source":"Annals of the New York Academy of Sciences","url":"https://pubmed.ncbi.nlm.nih.gov/10818516","citation_count":22,"is_preprint":false},{"pmid":"31443114","id":"PMC_31443114","title":"TMZ regulates GBM stemness via MMP14-DLL4-Notch3 pathway.","date":"2019","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/31443114","citation_count":22,"is_preprint":false},{"pmid":"12480754","id":"PMC_12480754","title":"Lessons from CADASIL.","date":"2002","source":"Annals of the New York Academy of Sciences","url":"https://pubmed.ncbi.nlm.nih.gov/12480754","citation_count":20,"is_preprint":false},{"pmid":"23847153","id":"PMC_23847153","title":"Headache among CADASIL patients with R544C mutation: prevalence, characteristics, and associations.","date":"2013","source":"Cephalalgia : an international journal of headache","url":"https://pubmed.ncbi.nlm.nih.gov/23847153","citation_count":19,"is_preprint":false},{"pmid":"36221938","id":"PMC_36221938","title":"Elderly CADASIL patients with intact neurological status.","date":"2022","source":"Journal of stroke","url":"https://pubmed.ncbi.nlm.nih.gov/36221938","citation_count":18,"is_preprint":false},{"pmid":"31960911","id":"PMC_31960911","title":"Naturally occurring NOTCH3 exon skipping attenuates NOTCH3 protein aggregation and disease severity in CADASIL patients.","date":"2020","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/31960911","citation_count":18,"is_preprint":false},{"pmid":"29304760","id":"PMC_29304760","title":"Regulation of pancreatic stellate cell activation by Notch3.","date":"2018","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/29304760","citation_count":18,"is_preprint":false},{"pmid":"17996090","id":"PMC_17996090","title":"CADASIL in Arabs: clinical and genetic findings.","date":"2007","source":"BMC medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/17996090","citation_count":18,"is_preprint":false},{"pmid":"36232798","id":"PMC_36232798","title":"Genotype and Phenotype Differences in CADASIL from an Asian Perspective.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36232798","citation_count":17,"is_preprint":false},{"pmid":"19542611","id":"PMC_19542611","title":"On the diagnosis of CADASIL.","date":"2009","source":"Journal of Alzheimer's disease : JAD","url":"https://pubmed.ncbi.nlm.nih.gov/19542611","citation_count":17,"is_preprint":false},{"pmid":"12480760","id":"PMC_12480760","title":"Clinical Features of CADASIL.","date":"2002","source":"Annals of the New York Academy of Sciences","url":"https://pubmed.ncbi.nlm.nih.gov/12480760","citation_count":17,"is_preprint":false},{"pmid":"21504125","id":"PMC_21504125","title":"Glial vascular degeneration in CADASIL.","date":"2010","source":"Journal of Alzheimer's disease : JAD","url":"https://pubmed.ncbi.nlm.nih.gov/21504125","citation_count":17,"is_preprint":false},{"pmid":"25150590","id":"PMC_25150590","title":"Latent NOTCH3 epitopes unmasked in CADASIL and regulated by protein redox state.","date":"2014","source":"Brain research","url":"https://pubmed.ncbi.nlm.nih.gov/25150590","citation_count":16,"is_preprint":false},{"pmid":"38254727","id":"PMC_38254727","title":"Progress to Clarify How NOTCH3 Mutations Lead to CADASIL, a Hereditary Cerebral Small Vessel Disease.","date":"2024","source":"Biomolecules","url":"https://pubmed.ncbi.nlm.nih.gov/38254727","citation_count":15,"is_preprint":false},{"pmid":"28281108","id":"PMC_28281108","title":"Recognizing CADASIL: a Secondary Cause of Migraine with Aura.","date":"2017","source":"Current pain and headache reports","url":"https://pubmed.ncbi.nlm.nih.gov/28281108","citation_count":15,"is_preprint":false},{"pmid":"27890607","id":"PMC_27890607","title":"Genotype-phenotype correlations of cysteine replacement in CADASIL.","date":"2016","source":"Neurobiology of aging","url":"https://pubmed.ncbi.nlm.nih.gov/27890607","citation_count":15,"is_preprint":false},{"pmid":"27102435","id":"PMC_27102435","title":"N-acetylcysteine negatively regulates Notch3 and its malignant signaling.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27102435","citation_count":15,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":47958,"output_tokens":7086,"usd":0.125082,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":16315,"output_tokens":6972,"usd":0.127938,"stage2_stop_reason":"end_turn"},"total_usd":0.25302,"stage1_batch_id":"msgbatch_013a8chtv3AWyTqv4z4sEF4C","stage2_batch_id":"msgbatch_01AHsuW63vinsvuTgzmQ3n62","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1996,\n      \"finding\": \"Mutations in the NOTCH3 gene were identified as causative for CADASIL; the mutations map to the CADASIL critical region on chromosome 19 and cause serious disruption of the Notch3 receptor, establishing NOTCH3 as the defective gene in CADASIL patients.\",\n      \"method\": \"Positional cloning, sequence analysis, genetic linkage analysis\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — positional cloning with co-segregation analysis, replicated across multiple families, foundational discovery replicated by many subsequent studies\",\n      \"pmids\": [\"8878478\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"CADASIL mutations in NOTCH3 are strongly clustered within the EGF-like repeats of the extracellular domain and are stereotyped missense mutations that all cause loss or gain of a cysteine residue, resulting in an unpaired number of cysteine residues within a given EGF domain; this suggests aberrant dimerization of Notch3 via abnormal disulfide bridging.\",\n      \"method\": \"SSCP, heteroduplex analysis, Sanger sequencing of 50 unrelated CADASIL patients and 100 controls\",\n      \"journal\": \"Lancet\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct mutational screening with controls, replicated in many subsequent studies across populations\",\n      \"pmids\": [\"9388399\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"In normal tissues NOTCH3 expression is restricted to vascular smooth muscle cells; NOTCH3 undergoes proteolytic cleavage producing a 210-kDa extracellular fragment and a 97-kDa intracellular fragment; in CADASIL brains the 210-kDa ectodomain selectively accumulates at the cytoplasmic membrane of vascular smooth muscle cells, while the cytosolic domain does not accumulate, indicating that CADASIL mutations specifically impair clearance of the Notch3 ectodomain from the cell surface.\",\n      \"method\": \"Immunohistochemistry, Western blot, transfected cell analysis, post-mortem CADASIL brain tissue analysis\",\n      \"journal\": \"Journal of Clinical Investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (IHC, Western blot, cell transfection), replicated finding across patient samples\",\n      \"pmids\": [\"10712431\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"CADASIL mutations in NOTCH3 do not affect the addition of O-fucose to EGF-like repeats but do impair carbohydrate chain elongation by Fringe (O-fucosyltransferase-dependent glycosylation); additionally, CADASIL mutations induce aberrant homodimerization of mutant Notch3 fragments and heterodimerization with Lunatic Fringe, implicating Fringe in CADASIL pathophysiology.\",\n      \"method\": \"Biochemical glycosylation assays on Notch3 EGF-like repeat fragments, in vitro dimerization assays\",\n      \"journal\": \"Human Molecular Genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro biochemical assay with mutant constructs, multiple orthogonal readouts in single study\",\n      \"pmids\": [\"15857853\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"The archetypal CADASIL mutation R90C in NOTCH3 retains normal canonical Notch signaling activity in brain arteries in vivo (normal RBP-Jk-mediated activity) and does not exhibit dominant-negative activity even when the ectodomain accumulates; this suggests CADASIL pathogenesis involves novel pathogenic roles of mutant NOTCH3 rather than loss of canonical NOTCH3 signaling function.\",\n      \"method\": \"Genetic rescue experiments in Notch3-/- mice using transgenic expression of wild-type or R90C mutant human NOTCH3 at physiological levels; in vivo NOTCH3/RBP-Jk activity assessment\",\n      \"journal\": \"Human Molecular Genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — genetic epistasis/rescue in vivo with functional signaling readout, rigorous comparison of WT vs mutant at matched expression levels\",\n      \"pmids\": [\"17331978\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Both wild-type and CADASIL-mutated NOTCH3 ectodomain spontaneously form oligomers and higher-order multimers via disulfide bonds in vitro; CADASIL-associated mutations significantly enhance multimerization compared to wild-type, providing experimental evidence for a neomorphic effect of CADASIL mutations promoting N3ECD self-association and accumulation.\",\n      \"method\": \"In vitro multimerization assays, single-molecule analysis ('scanning for intensely fluorescent targets'), biochemical characterization\",\n      \"journal\": \"Human Molecular Genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution with single-molecule analysis, multiple methods in one study\",\n      \"pmids\": [\"19417009\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Thrombospondin-2 (TSP2), but not TSP1, directly binds to NOTCH3 and Jagged1 and augments the interaction between Notch3 and Jagged1, thereby enhancing Notch3 signal transduction potency; loss of TSP2 in knockout mice reduces Notch target gene expression, identifying TSP2 as an extracellular intermediary that facilitates Notch3-Jagged1 receptor-ligand interactions.\",\n      \"method\": \"Direct binding assays (TSP2 pulldown with Notch3 and Jagged1), TSP2 knockout mouse analysis, Notch target gene expression measurement, cancer cell proliferation assays\",\n      \"journal\": \"Journal of Biological Chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct binding demonstrated, genetic KO validation with functional readout, multiple orthogonal methods\",\n      \"pmids\": [\"19147503\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Degradation of both the intracellular domain (N3-ICD) and the extracellular domain (N3-ECD) of Notch3 is mediated by lysosomes, not by the ubiquitin-proteasome system; lysosome inhibitors (chloroquine, NH4Cl) caused accumulation and delayed degradation of N3-ICD, while proteasome inhibitors (MG132, lactacystin) had no effect, distinguishing Notch3 turnover from Notch1 and Notch4.\",\n      \"method\": \"Pharmacological inhibitor experiments (lysosome vs. proteasome inhibitors) in transfected 293 cells and endogenous N3-ICD in C2C12, H460, and HeLa cell lines; Western blot\",\n      \"journal\": \"International Journal of Biochemistry & Cell Biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple cell lines, multiple inhibitors, direct comparison of lysosome vs. proteasome pathways, consistent results\",\n      \"pmids\": [\"19735738\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Notch3 is required in mural cells for retinal vascular development; Notch3-deficient mice exhibit reduced retinal vascularization, diminished sprouting, reduced mural cell investment, and loss of vessel coverage; Notch3 also regulates angiopoietin-2 expression in mural cells (Notch3 is sufficient for angiopoietin-2 induction, enhanced by HIF-1α), and pathological neovascularization in oxygen-induced retinopathy is decreased in Notch3-null mice.\",\n      \"method\": \"Notch3 knockout mice, oxygen-induced retinopathy model, in vitro Notch3 overexpression assays for angiopoietin-2 induction, immunostaining\",\n      \"journal\": \"Circulation Research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO with defined vascular phenotype, in vitro mechanistic validation, multiple readouts\",\n      \"pmids\": [\"20689064\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"NOTCH3 forms heterodimers with NOTCH1, NOTCH3, and NOTCH4; CADASIL mutant NOTCH3 (R90C, C49Y) forms complexes more resistant to detergents than wild-type; mutant NOTCH3 shows significantly inhibited clearance; overexpressed wild-type and mutant NOTCH3 protein repress NOTCH-regulated smooth muscle transcripts and impair the activity of smooth muscle promoters, suggesting that NOTCH3 accumulation interferes with canonical Notch function in smooth muscle cells.\",\n      \"method\": \"Co-immunoprecipitation for heterodimer detection, quantitative NOTCH3-luciferase clearance assays, coculture NOTCH functional assays, smooth muscle promoter reporter assays\",\n      \"journal\": \"PLoS One\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal co-IP and functional reporter assays, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"23028706\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Ligand-induced proteolytic activation of NOTCH3 (and NOTCH2) requires sequential cleavage by ADAM10 metalloprotease followed by intramembranous cleavage by the presenilin-containing γ-secretase complex; ADAM17/TACE plays no role in ligand-induced NOTCH2 or NOTCH3 signaling, establishing canonical ligand-induced processing of NOTCH3 as strictly ADAM10- and presenilin-dependent.\",\n      \"method\": \"Cell-based proteolytic activation assays with Delta-Jagged-type ligands, ADAM10 and presenilin knockdown/knockout, signaling readouts\",\n      \"journal\": \"Molecular and Cellular Biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic knockouts combined with functional signaling readouts, explicit negative result for ADAM17, rigorous mechanistic dissection\",\n      \"pmids\": [\"24842903\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"LTBP-1 (latent TGF-β binding protein 1) directly interacts with NOTCH3-ECD and co-aggregates specifically with mutant Notch3-ECD deposits in CADASIL vessel walls; fibronectin and fibrillin-1 are also enriched in CADASIL vessels but do not co-localize with Notch3-ECD deposits; TGF-β prodomain (LAP) levels are increased in CADASIL, indicating dysregulation of TGF-β pathway via sequestration by Notch3-ECD aggregates.\",\n      \"method\": \"Immunohistochemistry of post-mortem CADASIL brain tissue, in vitro direct interaction assay between LTBP-1 and Notch3-ECD, co-aggregation assays\",\n      \"journal\": \"Acta Neuropathologica Communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct binding demonstrated in vitro plus IHC in patient tissue, single lab\",\n      \"pmids\": [\"25190493\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Endogenous Notch3 signaling via Jag1 and Jag2 ligands selectively controls the pool of undifferentiated progenitors of upper airways; disruption of Notch3 signaling (genetic and pharmacological) causes aberrant expansion of basal cells and altered pseudostratification; Notch3-dependent parabasal cells subsequently activate Notch1 and Notch2 for secretory-multiciliated cell fate selection.\",\n      \"method\": \"Genetic knockouts, pharmacological inhibition, airway organotypic culture, human lung tissue analysis\",\n      \"journal\": \"Development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic and pharmacological approaches combined, defined cellular phenotype with pathway placement, validated in human tissue\",\n      \"pmids\": [\"25564622\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Notch3 drives cholangiocarcinoma development and progression via a non-canonical pathway independent of RBPJ; Notch3 promotes tumor cell survival via activation of PI3K-Akt; genetic knockout of Notch3 significantly attenuates tumor growth.\",\n      \"method\": \"Notch3 genetic knockout studies in transgenic mouse model and rat model, PI3K-Akt pathway analysis, human CC characterization\",\n      \"journal\": \"Proceedings of the National Academy of Sciences\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO with defined tumor growth phenotype, mechanistic pathway identification (PI3K-Akt), validated across species\",\n      \"pmids\": [\"27791012\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Notch3 signaling is both necessary and sufficient to support mural cell coverage in arteries; systemic administration of an agonist Notch3 antibody prevents mural cell loss in CADASIL mice (C455R mutation) and modifies plasma proteins including endostatin/collagen 18α1 and Notch3 ECD; genetic rescue in Notch3 knockout mice demonstrated necessity and sufficiency of Notch3 for mural cell maintenance.\",\n      \"method\": \"Genetic rescue in Notch3 knockout mice, agonist antibody treatment in CADASIL mouse model, plasma protein analysis\",\n      \"journal\": \"Journal of Experimental Medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic rescue with KO mice plus pharmacological agonist antibody, multiple readouts including plasma biomarkers\",\n      \"pmids\": [\"28698285\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Notch3 functions as a dependence receptor in endothelial cells, inducing apoptosis in the absence of its ligand Jagged-1; Jagged-1 produced by cancer cells blocks this pro-apoptotic activity; using Notch3 mutant mice, tumor growth and angiogenesis increase when Notch3 is silenced in stroma, and the anti-tumor effect of γ-secretase inhibition is partly dependent on Notch3-triggered apoptosis in endothelial cells.\",\n      \"method\": \"Notch3 mutant mice, genetic silencing, endothelial cell apoptosis assays, tumor implantation models\",\n      \"journal\": \"Nature Communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO with tumor growth phenotype, mechanistic apoptosis assays, multiple experimental models\",\n      \"pmids\": [\"28719575\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"NOTCH3 is expressed in NG2+PDGFRβ+ perivascular hemangioma stem cells (HemSCs) and is necessary for HemSC-to-mural cell differentiation; NOTCH3 knockdown in HemSCs inhibits mural cell differentiation and perturbs αSMA expression; in a mouse IH model, NOTCH3 knockdown or NOTCH3 Decoy expression decreases IH blood flow, vessel caliber, and αSMA+ perivascular cell coverage.\",\n      \"method\": \"NOTCH3 knockdown in HemSCs, mouse IH model, NOTCH3 Decoy transgenic expression, flow cytometry, immunostaining\",\n      \"journal\": \"JCI Insight\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — loss-of-function with defined cellular phenotype in vitro and in vivo, multiple orthogonal approaches\",\n      \"pmids\": [\"29093274\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"CADASIL vasculopathy involves a Notch3-Nox5/ER stress/ROCK signaling mechanism; NOTCH3 mutations in VSMCs induce Nox5 upregulation, leading to increased ER stress response, Rho kinase activity, superoxide production, and cytoskeleton-associated protein phosphorylation; inhibitors of Notch3 (γ-secretase inhibitor), Nox5, ER stress, and ROCK each ameliorate aberrant vascular responses in CADASIL patient arteries and TgNotch3R169C mice.\",\n      \"method\": \"Peripheral small artery isolation from CADASIL patients and CADASIL mouse model, pharmacological inhibitors, gene expression analysis, functional vascular assays\",\n      \"journal\": \"JCI Insight\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — human patient tissue plus mouse model, multiple pharmacological interventions with consistent results, pathway placement established\",\n      \"pmids\": [\"31647781\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"MMP14 nuclear translocation following TMZ treatment promotes extracellular release of DLL4, which stimulates cleavage of Notch3 and its nuclear translocation, inducing sphering capacity and stemness in glioblastoma cells.\",\n      \"method\": \"Subcellular localization studies, Kiloplex ELISA-based array, functional stemness assays in PDX GBM models and established cell lines\",\n      \"journal\": \"International Journal of Cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — mechanistic pathway placement with functional readouts, single lab, limited mechanistic depth for NOTCH3 specifically\",\n      \"pmids\": [\"31443114\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Pericyte NOTCH3 and endothelial NOTCH1 cooperate for pericyte-induced stabilization of the vasculature; loss of either NOTCH3 or NOTCH1 decreases VE-cadherin accumulation at endothelial adherens junctions and increases junction motility; DLL4 is the key ligand for NOTCH1 activation in endothelial cells, and DLL4 expression in pericytes is dependent on NOTCH3.\",\n      \"method\": \"In vitro vascular models with pericyte-endothelial coculture, NOTCH3 and NOTCH1 loss-of-function, VE-cadherin imaging, DLL4 expression analysis\",\n      \"journal\": \"American Journal of Physiology: Cell Physiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — defined cellular phenotype with loss-of-function, pathway placement via ligand identification, multiple readouts in single study\",\n      \"pmids\": [\"34878922\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"In elastin deficiency, reduced elastin induces epigenetic upregulation of the NOTCH pathway in SMCs, specifically activating NOTCH3 intracellular domain via increased γ-secretase; JAGGED1 produced by SMCs (not endothelial cells) is the key ligand driving NOTCH3 activation; Notch3 deletion or γ-secretase inhibition attenuates aortic hypermuscularization and stenosis in Eln-/- mice.\",\n      \"method\": \"Human aortic vascular cells, Eln-/- mouse models, iPSC-derived SMCs from ELN-deficient patients, Notch3 genetic deletion, Jag1 conditional deletion in SMCs vs ECs, pharmacological γ-secretase inhibition\",\n      \"journal\": \"Journal of Clinical Investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO with cell-type-specific conditional deletion, human and mouse models, multiple orthogonal methods\",\n      \"pmids\": [\"34990407\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Wild-type Notch3-ECD co-aggregates with mutant Notch3-ECD; elimination of one copy of wild-type Notch3 in TgNotch3R169C mice is sufficient to attenuate Notch3-ECD accumulation and arterial pathology (SMC loss); Notch3-regulated gene expression is essentially unchanged in TgNotch3R169C arteries, indicating that ECD accumulation (not loss of signaling) is the major driver of arterial SMC loss in CADASIL.\",\n      \"method\": \"Dedicated histopathological and multiscale imaging modalities in transgenic and knockin Notch3 mouse models, quantitative SMC loss measurement, Notch3-regulated gene expression profiling, co-aggregation assays\",\n      \"journal\": \"Journal of Clinical Investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple mouse genetic models (transgenic vs knockin), quantitative pathology, gene expression profiling, direct co-aggregation evidence\",\n      \"pmids\": [\"38386425\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"CHAC1, upregulated by TMZ via the JNK1/c-JUN pathway, binds directly to the Notch3 protein and inhibits Notch3 activation, attenuating Notch3-mediated downstream signaling; TMZ also significantly reduces Notch3 levels in glioma cells.\",\n      \"method\": \"Transcriptome microarray, CHAC1 overexpression/knockdown, co-immunoprecipitation of CHAC1 with Notch3, signaling pathway analysis in GBM cell lines\",\n      \"journal\": \"Neuropharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — co-IP demonstrating CHAC1-Notch3 binding, functional signaling readout, single lab\",\n      \"pmids\": [\"27986595\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"N-acetylcysteine (NAC) reduces Notch3 (specifically the cleaved intracellular domain N3ICD) protein levels through lysosome-dependent degradation in a manner independent of γ-secretase or glutathione; NAC does not affect full-length Notch3 precursor or ectopically expressed N3ICD, and does not alter Notch3 mRNA, indicating post-translational regulation at the level of processed N3ICD.\",\n      \"method\": \"Pharmacological inhibition (lysosome vs. proteasome inhibitors), NAC treatment in HeLa and multiple cancer cell lines, Western blot, mRNA analysis, Notch3 silencing and N3ICD overexpression\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple cell lines, multiple inhibitors, orthogonal genetic and pharmacological approaches, single lab\",\n      \"pmids\": [\"27102435\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Deregulated Notch3 signaling enhances CXCR4 cell-surface expression and migratory ability of CD4+CD8+ thymocytes; Notch3 regulates CXCR4 surface expression through β-arrestin in human leukemia cells; in vivo CXCR4 antagonism prevents bone marrow colonization by CD4+CD8+ cells in young Notch3 transgenic mice.\",\n      \"method\": \"Notch3 intracellular domain transgenic mice, transplantation assays, CXCR4 surface expression analysis, β-arrestin mechanistic studies in human leukemia cells, in vivo CXCR4 antagonism\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — transgenic mouse model with in vivo pharmacological intervention, mechanistic β-arrestin finding in human cells, single lab\",\n      \"pmids\": [\"30038265\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Naturally occurring NOTCH3 exon 9 skipping in a patient with a Gly498Cys NOTCH3 variant effectively excludes the mutation from the majority of transcripts, resulting in attenuated NOTCH3 protein aggregation (no GOM detected, minimal NOTCH3 staining in skin biopsy) and a milder CADASIL phenotype; therapeutic exon 9 skipping can be achieved in cell models using antisense oligonucleotides and CRISPR/Cas9, providing proof-of-concept that cysteine-corrective exon skipping reduces NOTCH3 aggregation.\",\n      \"method\": \"RT-PCR and Sanger sequencing of patient fibroblast RNA, skin biopsy electron microscopy and immunohistochemistry, antisense-mediated exon skipping in cell models, CRISPR/Cas9 genome editing\",\n      \"journal\": \"Human Molecular Genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — natural human experiment plus cell model validation with two orthogonal therapeutic approaches, direct biochemical measurement of aggregation\",\n      \"pmids\": [\"31960911\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"NOTCH3 is a transmembrane receptor expressed predominantly in vascular smooth muscle cells and pericytes that undergoes regulated proteolysis (ADAM10 then γ-secretase/presenilin) to release a 210-kDa ectodomain and a 97-kDa intracellular domain (N3-ICD) whose degradation is lysosome-dependent; the receptor signals canonically via RBP-Jk to control arterial SMC identity and mural cell investment of vessels, acts non-canonically (RBPJ-independent, PI3K-Akt) in some contexts, and functions as a dependence receptor in endothelial cells; CADASIL-causing cysteine mutations in the EGF-like repeats of the ectodomain impair Fringe-mediated glycosylation and dramatically enhance disulfide bond-mediated ectodomain multimerization, causing selective accumulation of the 210-kDa ectodomain (together with wild-type ectodomain) at the SMC surface—this aggregation sequesters extracellular matrix proteins such as LTBP-1, activates ER stress and Rho kinase via Nox5, and drives progressive arterial SMC loss, while canonical Notch3 signaling activity per se is largely preserved.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"NOTCH3 is a single-pass transmembrane receptor expressed predominantly in vascular smooth muscle cells and mural/pericyte populations, where it governs mural cell investment and stabilization of the developing and mature vasculature [#2, #8, #14]. Ligand engagement triggers sequential proteolysis—an ADAM10 metalloprotease cut followed by intramembranous cleavage by the presenilin-containing γ-secretase complex—releasing a ~210-kDa ectodomain and a ~97-kDa intracellular domain (N3-ICD), both of which are cleared through lysosome-dependent rather than proteasomal degradation [#2, #10, #7]. Canonically NOTCH3 signals through RBP-Jk to specify smooth muscle/mural cell programs, and this activity drives mural cell coverage of arteries and cooperates with endothelial NOTCH1 to maintain VE-cadherin junctions [#14, #19]; ligand availability is shaped by extracellular intermediaries including Thrombospondin-2, which bridges NOTCH3 to Jagged1 [#6], and by Jagged1 produced within smooth muscle, which drives NOTCH3 activation in elastin deficiency [#20]. Beyond this canonical axis, NOTCH3 acts non-canonically through PI3K-Akt to promote tumor cell survival in cholangiocarcinoma [#13] and behaves as a dependence receptor in endothelial cells, inducing apoptosis when Jagged-1 is absent [#15]. NOTCH3 is the causative gene in CADASIL, where stereotyped cysteine-altering missense mutations in the EGF-like repeats of the ectodomain create unpaired cysteines [#0, #1]; these mutations impair Fringe-mediated glycosylation and dramatically enhance disulfide-bonded ectodomain multimerization, causing selective surface accumulation of the 210-kDa ectodomain together with co-aggregating wild-type ectodomain [#3, #5, #21]. This aggregation, rather than loss of canonical signaling, drives arterial smooth muscle cell loss—canonical RBP-Jk activity is preserved in mutant receptors—and operates by sequestering matrix proteins such as LTBP-1 and engaging a Nox5/ER stress/Rho-kinase cascade [#4, #11, #17, #21].\",\n  \"teleology\": [\n    {\n      \"year\": 1997,\n      \"claim\": \"Having established NOTCH3 as the CADASIL gene, the question became what kind of lesion the mutations represent; finding that they are stereotyped cysteine gains/losses clustered in ectodomain EGF repeats defined a mutational signature and predicted abnormal disulfide bridging.\",\n      \"evidence\": \"Mutational screening of CADASIL patients and controls by SSCP, heteroduplex analysis, and Sanger sequencing, following positional cloning\",\n      \"pmids\": [\"8878478\", \"9388399\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not show how unpaired cysteines lead to protein-level dysfunction\", \"No demonstration of aggregation in tissue at this stage\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"It was unknown which NOTCH3 fragment is affected in disease; demonstrating that the 210-kDa ectodomain selectively accumulates at the VSMC surface in CADASIL brains while the intracellular domain does not established a clearance defect specific to the ectodomain.\",\n      \"evidence\": \"IHC, Western blot, and transfected cell analysis of post-mortem CADASIL brain tissue\",\n      \"pmids\": [\"10712431\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not establish whether accumulation is cause or consequence of disease\", \"Mechanism of impaired ectodomain clearance not defined\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"To explain how cysteine mutations cause accumulation, glycosylation and dimerization were tested; mutations were shown to spare O-fucose addition but impair Fringe-mediated chain elongation and to drive aberrant homo/heterodimerization, implicating glycosylation and abnormal self-association in pathology.\",\n      \"evidence\": \"In vitro biochemical glycosylation and dimerization assays on Notch3 EGF-like repeat fragments\",\n      \"pmids\": [\"15857853\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Used isolated fragments rather than full-length receptor\", \"Did not quantify multimerization or link to tissue accumulation\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"A central question was whether CADASIL is loss- or gain-of-function; in vivo rescue showing R90C retains normal RBP-Jk activity and lacks dominant-negative effect established that pathogenesis involves a novel toxic role rather than canonical signaling loss.\",\n      \"evidence\": \"Genetic rescue in Notch3-/- mice with WT or R90C human NOTCH3 at physiological levels, with in vivo signaling readout\",\n      \"pmids\": [\"17331978\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not identify the toxic mechanism downstream of ectodomain accumulation\", \"Single mutation tested\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"The biophysical basis of accumulation was unresolved; single-molecule and biochemical assays showed both WT and mutant ectodomains form disulfide-linked multimers with mutations markedly enhancing multimerization, providing direct evidence for a neomorphic self-association defect, while parallel work assigned NOTCH3 turnover to the lysosome.\",\n      \"evidence\": \"In vitro multimerization and single-molecule fluorescence assays; pharmacological lysosome vs proteasome inhibitor experiments across multiple cell lines\",\n      \"pmids\": [\"19417009\", \"19735738\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not reconstitute multimerization in vivo at this stage\", \"Lysosomal targeting signal/machinery not identified\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"How NOTCH3-ligand engagement is modulated extracellularly was unclear; identifying Thrombospondin-2 as a direct binder of NOTCH3 and Jagged1 that augments their interaction defined an extracellular amplifier of NOTCH3 signaling.\",\n      \"evidence\": \"Direct binding/pulldown assays, TSP2 knockout mouse analysis, and Notch target gene expression\",\n      \"pmids\": [\"19147503\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"TSP2 role in CADASIL or vascular maintenance not tested\", \"Structural basis of the ternary interaction unknown\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"The physiological vascular role of NOTCH3 was incompletely defined; knockout mice revealed it is required in mural cells for retinal vascularization, sprouting, and vessel coverage, and regulates angiopoietin-2, placing NOTCH3 in mural cell investment of vessels.\",\n      \"evidence\": \"Notch3 knockout mice, oxygen-induced retinopathy model, in vitro angiopoietin-2 induction assays, immunostaining\",\n      \"pmids\": [\"20689064\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not resolve which ligands drive this in vivo\", \"Connection to CADASIL SMC loss not established\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Whether mutant NOTCH3 might also impair canonical function was revisited; co-IP and reporter assays showed mutant heterodimers are detergent-resistant and poorly cleared and that NOTCH3 overexpression represses smooth muscle transcripts, raising a possible interference with canonical function in SMCs.\",\n      \"evidence\": \"Reciprocal co-IP for heterodimer detection, NOTCH3-luciferase clearance assays, and smooth muscle promoter reporter assays\",\n      \"pmids\": [\"23028706\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Relied on overexpression, which may not reflect physiological signaling\", \"Apparent tension with in vivo rescue showing preserved signaling not resolved\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"The proteases required for NOTCH3 activation were undefined; functional assays established ligand-induced activation requires ADAM10 then presenilin/γ-secretase, with ADAM17/TACE playing no role, defining the canonical processing pathway.\",\n      \"evidence\": \"Cell-based proteolytic activation assays with ADAM10/presenilin knockdown-knockout and signaling readouts\",\n      \"pmids\": [\"24842903\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not address ligand-independent or aberrant processing in disease\", \"Regulation of protease access not studied\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"The matrix consequences of ectodomain aggregation were unknown; identifying LTBP-1 as a direct binder that co-aggregates specifically with mutant Notch3-ECD deposits, with increased TGF-β prodomain levels, established sequestration of matrix/TGF-β components as a pathogenic mechanism.\",\n      \"evidence\": \"IHC of post-mortem CADASIL tissue plus in vitro direct interaction and co-aggregation assays\",\n      \"pmids\": [\"25190493\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional consequence of TGF-β dysregulation for SMC loss not demonstrated\", \"Single-lab IHC correlation\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"NOTCH3's role in non-vascular tissue was unclear; airway studies showed endogenous NOTCH3 signaling via Jag1/Jag2 controls undifferentiated progenitor pools and precedes NOTCH1/NOTCH2-driven fate selection, extending NOTCH3 function to epithelial progenitor regulation.\",\n      \"evidence\": \"Genetic knockouts, pharmacological inhibition, airway organotypic culture, and human lung tissue analysis\",\n      \"pmids\": [\"25564622\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream transcriptional targets in airway not detailed\", \"Relevance to vascular NOTCH3 biology not connected\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Whether NOTCH3 signals only canonically was tested in cancer; cholangiocarcinoma studies showed NOTCH3 drives tumor survival and growth via an RBPJ-independent PI3K-Akt pathway, establishing a non-canonical NOTCH3 mode.\",\n      \"evidence\": \"Notch3 genetic knockout in mouse and rat models, PI3K-Akt pathway analysis, human tumor characterization\",\n      \"pmids\": [\"27791012\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular link between NOTCH3 and PI3K-Akt not defined\", \"Generality across tumor types untested here\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Post-translational control of N3-ICD was probed pharmacologically; CHAC1 was shown to bind NOTCH3 and inhibit its activation, and N-acetylcysteine was shown to lower cleaved N3-ICD via lysosomal degradation, identifying modulators of NOTCH3 protein levels and signaling.\",\n      \"evidence\": \"Co-IP of CHAC1 with NOTCH3 and signaling assays; NAC treatment with lysosome/proteasome inhibitors, silencing, and N3ICD overexpression across cancer cell lines\",\n      \"pmids\": [\"27986595\", \"27102435\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"CHAC1-NOTCH3 interaction is single-lab co-IP without structural detail\", \"NAC mechanism on endogenous N3ICD versus ectopic differs and is unexplained\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"The vascular dependence of NOTCH3 and its therapeutic accessibility were addressed together; genetic rescue and agonist antibody studies showed NOTCH3 is necessary and sufficient for arterial mural cell coverage and that agonism prevents mural cell loss in CADASIL mice, while separate work defined NOTCH3 as an endothelial dependence receptor inducing ligand-free apoptosis, and as essential for hemangioma stem cell-to-mural differentiation.\",\n      \"evidence\": \"Genetic rescue in Notch3 KO mice and agonist antibody treatment in CADASIL mice; dependence-receptor apoptosis assays in tumor models; NOTCH3 knockdown/Decoy in HemSCs and IH mouse model\",\n      \"pmids\": [\"28698285\", \"28719575\", \"29093274\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How the same receptor balances survival/mural-supportive and pro-apoptotic outputs not mechanistically unified\", \"Agonist antibody durability and specificity not fully characterized\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"A downstream effector cascade for CADASIL vasculopathy was missing; mutant NOTCH3 was shown to upregulate Nox5, raising ER stress, ROCK activity, and superoxide, with inhibitors of each step ameliorating aberrant vascular responses in patient arteries and mutant mice, defining a Nox5/ER stress/ROCK axis. In parallel, ligand-induced NOTCH3 cleavage and nuclear translocation were linked to glioblastoma stemness via MMP14/DLL4.\",\n      \"evidence\": \"CADASIL patient and mouse small-artery isolation with pharmacological inhibitors and functional vascular assays; subcellular localization and stemness assays in GBM models\",\n      \"pmids\": [\"31647781\", \"31443114\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Connection between ectodomain aggregation and intracellular Nox5 induction not fully resolved\", \"GBM MMP14/DLL4/NOTCH3 axis is single-lab and Medium confidence\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"A causal test of aggregation as the disease driver and a therapeutic strategy emerged together; natural exon 9 skipping in a Gly498Cys patient excluded the mutant cysteine and yielded attenuated aggregation and milder disease, with antisense and CRISPR approaches reproducing cysteine-corrective skipping, providing proof-of-concept that reducing aggregation is beneficial.\",\n      \"evidence\": \"Patient fibroblast RT-PCR/sequencing, skin biopsy EM/IHC, and antisense and CRISPR/Cas9 exon-skipping in cell models\",\n      \"pmids\": [\"31960911\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo efficacy of therapeutic exon skipping not demonstrated\", \"Applicability beyond skippable exons unclear\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"How NOTCH3 cooperates across the vessel wall was unresolved; pericyte-endothelial coculture showed pericyte NOTCH3 and endothelial NOTCH1 cooperate to stabilize VE-cadherin junctions, with DLL4 (NOTCH1 ligand) expression in pericytes dependent on NOTCH3, defining a cross-talk circuit for vascular stabilization.\",\n      \"evidence\": \"In vitro pericyte-endothelial coculture with NOTCH3/NOTCH1 loss-of-function, VE-cadherin imaging, and DLL4 expression analysis\",\n      \"pmids\": [\"34878922\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo validation of the NOTCH3→DLL4→NOTCH1 circuit not shown\", \"Relevance to CADASIL pathology not established\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Context-specific drivers of NOTCH3 activation in disease were defined; in elastin deficiency, reduced elastin epigenetically upregulates NOTCH3 with SMC-derived (not endothelial) JAGGED1 driving N3-ICD generation via increased γ-secretase, and Notch3 deletion or γ-secretase inhibition rescued aortic hypermuscularization and stenosis.\",\n      \"evidence\": \"Human aortic cells, Eln-/- mice, iPSC-derived patient SMCs, Notch3 deletion, cell-type-specific Jag1 deletion, and γ-secretase inhibition\",\n      \"pmids\": [\"34990407\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Epigenetic mechanism linking elastin loss to NOTCH3 not fully detailed\", \"Whether this axis operates in CADASIL untested\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"The definitive test of whether accumulation versus signaling loss drives CADASIL was performed; showing wild-type ectodomain co-aggregates with mutant and that removing one wild-type Notch3 copy attenuates ECD accumulation and arterial SMC loss while gene expression is unchanged established ectodomain accumulation as the major pathogenic driver.\",\n      \"evidence\": \"Transgenic and knockin Notch3 mouse models with multiscale imaging, quantitative SMC-loss measurement, gene expression profiling, and co-aggregation assays\",\n      \"pmids\": [\"38386425\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular trigger converting surface aggregates to SMC death not fully defined\", \"Translatability of wild-type-allele reduction to patients unestablished\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"It remains unresolved how the same NOTCH3 receptor reconciles its canonical RBP-Jk mural-cell program, non-canonical PI3K-Akt survival signaling, and dependence-receptor pro-apoptotic activity, and what molecular event converts surface ectodomain aggregates into the downstream Nox5/ER-stress/ROCK cascade that kills smooth muscle cells.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unifying model linking the three signaling modes\", \"Mechanistic bridge from extracellular aggregation to intracellular stress cascade undefined\", \"Structural basis of mutant ectodomain self-association not solved\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [10, 14, 19]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [4, 21]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [6]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [2, 9]},\n      {\"term_id\": \"GO:0005764\", \"supporting_discovery_ids\": [7, 23]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [18]},\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [2, 11]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [10, 13, 19]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [8, 12, 20]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [0, 17, 21]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [15]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [7, 10]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"JAG1\", \"JAG2\", \"DLL4\", \"THBS2\", \"LTBP1\", \"NOTCH1\", \"CHAC1\", \"ADAM10\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":6,"faith_pct":100.0}}